Search

Displaying results 4991 - 5000 of 7452 in total
  1. Drug

    GLB-005

    go.drugbank.com/drugs/DB32797
    Experimental

    GLB-005 is a molecular glue degrader targeting WIZ and is being investigated for treatment of sickle cell disease and β-thalassemia.[L56125, L56126, L56128]

  2. Drug

    Dihydroxyacetone phosphate

    go.drugbank.com/drugs/DB04326
    Investigational

    Dihydroxyacetone phosphate has been investigated for the treatment of Lymphoma, Large-Cell, Diffuse.

  3. Drug

    VLTS-934

    go.drugbank.com/drugs/DB05597
    Investigational

    VLTS-934 was developed by Valentis inc. for the treatment of Peripheral Arterial Disease (PAD).

  4. Drug

    Etrolizumab

    go.drugbank.com/drugs/DB12189
    Investigational

    [A244564, A244569, A244574, A244584] Etrolizumab is currently under investigation for the treatment of ulcerative colitis and Crohn's disease. … [A244564, A244584] Etrolizumab is a humanized IgG1κ monoclonal antibody directed against the β7 subunit of gastrointestinal α4β7 and αEβ7 integrins that, due to its target specificity, appears as or more

  5. Drug

    Dextranomer

    go.drugbank.com/drugs/DB13560
    Investigational

    Categories: Preparations for Treatment of Wounds and Ulcers, Compounds used in a research, industrial, or household setting
  6. Drug

    Aspergillus fumigatus

    go.drugbank.com/drugs/DB10425
    Approved

    Aspergillus fumigatus is a fungus which can provoke allergic reactions. Aspergillus fumigatus extract is used in allergenic testing.

    Mixtures: Number Four Mold Mixture
  7. Drug

    Epicriptine

    go.drugbank.com/drugs/DB11275
    Approved

    Epicriptine differs from the alpha form on the position of one methyl group.[T195] To know more about the mixture please visit [DB01049]

  8. Drug

    Dextrothyroxine

    go.drugbank.com/drugs/DB00509
    ApprovedWithdrawn

    Thyroxine is peripherally deiodinated to form triiodothyronine which exerts a broad spectrum of stimulatory effects on cell metabolism.

  9. Drug

    PI-0824

    go.drugbank.com/drugs/DB05516
    Investigational

    Peptimmune, Inc. has developed a new therapy for the treatment of PV, PI-0824. … It is hoped that use of PI-0824 will reduce or potentially eliminate the need for high dose steroids and drugs that suppress the immune system.

  10. Drug

    KD7040

    go.drugbank.com/drugs/DB05214
    Investigational

    KD7040 is a topically-delivered inducible nitric oxide synthase (iNOS) inhibitor for the treatment of neuropathic pain. The KD7040 IND was filed in 4Q06, and a Phase Ib clinical trial began 2Q07.